Business
Enterprise Partnership and Launch of PMx
Enterprise Partnership and Launch of PMx.
About this update from Diaceutics Plc
[{"type":"text","content":"\n\nGroundbreaking Enterprise Promotional Partnership and Launch of PMx\n \nDiaceutics will be the promotional partner with a leading biotech company for the launch of a breakthrough oncology precision medicine in the US\n \nDiaceutics will receive a success fee per patient prescription to a new and novel therapy\n \nPromotional partnership worth up to £4.3 million over first 18 months\n \nBelfast and London, 19 August 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce it has launched PMx, a suite of data-driven services built for the promotion and commercialisation of precision medicines and that it has reached agreement with a leading biotech to become its primary promotional partner for the launch of a breakthrough oncology precision medicine in the US using PMx. \nThis partnership represents Diaceutics' seventh enterprise-wide engagement, and the first PMx primary promotional partnership deal whereby Diaceutics' fee structure is aligned with patient recruitment onto therapy. PMx unlocks new revenue streams for Diaceutics and shows the path to considerable increase in revenue per brand.\nTerms of the Agreement\nUnder the terms of the agreement, Diaceutics will leverage its DxRx platform, specifically its best-in-class genomic lab data, lab network, omni-channel, digital and peer to peer physician education to enable drug commercialisation. Diaceutics' partner will retain all rights to the license for the drug.\nThis agreement is to deploy PMx through to the end of 2025 and is worth at least £2.4 million in service revenue to Diaceutics, with additional milestone fees estimated to be worth another £1.9 million payable during that period based on successful patient recruitment onto therapy. There is an expectation that the agreement will extend beyond 2025 should the initial phase be successful.\nRyan Keeling, Chief Executive Officer of Diaceutics commented: \"Today's announcement is a milestone for Diaceutics in three ways. Firstly, it's the start of a new era for Diaceutics, bringing together everything we have built in one solution, whilst providing a full promotional solution for this new partner and others in the future. Secondly, the construct of a PMx contract is different, allowing us to retain a gr...